We are dedicated to continuously generating novel antibodies and developing innovative immunoassays to quantify biomarkers across a broad spectrum of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Motor Neuron Diseases and other neurological conditions, such as psychiatric and sleep disorders.
As a Fujirebio company, our mission is to enable early detection and to accelerate drug discovery and development from the earliest research stages through to clinical decision-making, to ultimately improve the life of patients.